Purple Biotech (NASDAQ:PPBT) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Purple Biotech (NASDAQ:PPBT – Get Rating) in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Purple Biotech’s Q1 2023 earnings at ($0.35) EPS, Q2 2023 earnings […]